News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Issuance and repurchase of class C shares for incentive programs

December 16, 2024

Stockholm, Sweden, December 16, 2024. The Board of Directors for Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) has resolved to issue a total of 29,000,000 new class C shares and to immediately thereafter repurchase such 29,000,000 issued class C shares, for the purpose of the outstanding long-term incentive programs ESOP 2021, ESOP 2022, ESOP 2023 and ESOP 2024. The resolution by the Board of Directors was passed based on the authorizations granted by the annual general meeting held on May 6, 2024.
 
Svenska Handelsbanken AB (publ) will subscribe for all issued class C shares at a subscription price of approximately SEK 0.052632 per share, equal to the quota value of the shares. All 29,000,000 issued class C shares will be repurchased by Egetis Therapeutics AB (publ) for the same price per share. Following the share issuances, the share capital will increase by approximately SEK 1,526,316.36. The class C shares do not entitle to dividends and each share entitles to 1/10 voting right.
 
The purpose of the issuances and repurchase is to ensure future delivery of shares to participants in, as well as to cover any costs for social contributions arising as a result of, ESOP 2021, ESOP 2022, ESOP 2023 and ESOP 2024. The class C shares will be reclassified to ordinary shares before delivery to the participants in the programs.
 
Egetis Therapeutics AB (publ) will, following the issuances and repurchase of the 29,000,000 class C shares, hold all class C shares in the Company.

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]